In AD preclinical studies, MET reduced Tau phosphorylation in murine primary neurons expressing hTau via the activation of the PP2A phosphatase [98], and prevented amyloid plaques formation, cognitive impairment and chronic neuroinflammation in APP/PS1 mice [99]. This evidence concerns the gene MAPT and Alzheimer disease.